Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 3, Issue 8, 2013, Pages

  Weng, X Q ^a   Shen, Y ^a   Sheng, Y ^a   Chen, B ^a   Wang, J H ^a   Li, J M ^a   Mi, J Q ^a   Chen, Q S ^a   Zhu, Y M ^a   Jiang, C L ^a   Yan, H ^a   Zhang, X X ^a   Huang, T ^a   Zhu, Z ^a   Chen, Z ^a   Chen, S J ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

B acute lymphoblastic leukemia; Eight color flow cytometry; Leukemia associated immunophenotypes; Minimal residual disease; Prognosis

Indexed keywords

BCR ABL PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; B ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOBLAST; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; EIGHT COLOR FLOW CYTOMETRY; FEMALE; FLOW CYTOMETRY; FUSION GENE; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOPHENOTYPING; LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84882967201     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.31     Document Type: Article

References (49)

1. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2011: 231-237
2. Chen B, Wang YY, Shen Y, Zhang WN, He HY, Zhu YM et al. Newly diagnosed acute lymphoblastic leukemia in China (I): Abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries. Leukemia 2012; 26: 1608-1616
3. Mi JQ, Wang X, Yao Y, Lu HJ, Jiang XX, Zhou JF et al. Newly diagnosed acute lymphoblastic leukemia in China (II): Prognosis related to genetic abnormalities in a series of 1091 cases. Leukemia 2012; 26: 1507-1516
4. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1083-1098vii
5. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program; 2010: 7-12
6. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38: 139-152 (Pubitemid 29390417)
7. Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005; 128: 774-782 (Pubitemid 40444869)
8. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118 (Pubitemid 29043725)
9. Szczepanski T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ. Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 2001; 15: 1415-1423 (Pubitemid 32785311)
10. Bruggemann M, Droese J, Bolz I, Luth P, Pott C, von Neuhoff N et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 2000; 14: 1419-1425 (Pubitemid 30599323)
11. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 2008; 111: 5477-5485
12. Denys B, van der Sluijs-Gelling AJ, Homburg C, van der Schoot CE, de Haas V, Philippe J et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2012; 27: 635-641
13. Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003; 17: 138-148 (Pubitemid 36175899)
14. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom 2008; 74: 331-340
15. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T et al. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in cute leukemia: International Standardization and Clinical Evaluation. Leukemia 2001; 15: 1185-1192
16. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100: 52-58 (Pubitemid 35177428)
17. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317 (Pubitemid 38072572)
18. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611 (Pubitemid 46444541)
19. Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521-535
20. Garand R, Beldjord K, Cave H, Fossat C, Arnoux I, Asnafi V et al. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: A French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 2012; 27: 370-376
21. Solly F, Angelot F, Garand R, Ferrand C, Seilles E, Schillinger F et al. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry. Cytometry A 2012; 81: 17-24
22. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117: 6267-6276
23. Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006; 130: 680-690 (Pubitemid 43736872)
24. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986-2010
25. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975
26. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738 (Pubitemid 28534955)
27. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696
28. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214
29. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077-2084
30. Vidriales MB, Perez JJ, Lopez-Berges MC, Gutierrez N, Ciudad J, Lucio P et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: Early immunophenotypic evaluation has high clinical value. Blood 2003; 101: 4695-4700 (Pubitemid 36857722)
31. Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 2008; 142: 227-237 (Pubitemid 351994055)
32. Bruggemann M, Raff T, Flohr T, Gokbuget N, Nakao M, Droese J et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116-1123 (Pubitemid 43156313)
33. Bruggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 2012; 120: 4470-4481
34. Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120: 1868-1876
35. Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials. Blood 2007; 109: 910-915 (Pubitemid 46220634)
36. Gokbuget N, Kneba M, Raff T, Bruggemann M, Scheuring U, Reutzel R et al. Risk-adapted treatment according to minimal residual disease in adult ALL. Best Pract Res Clin Haematol 2002; 15: 639-652
37. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia 2003; 17: 2474-2486 (Pubitemid 38072587)
38. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357 (Pubitemid 38072573)
39. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98: 2498-2507
40. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958 (Pubitemid 34525474)
41. Griesinger F, Piro-Noack M, Kaib N, Falk M, Renziehausen A, Troff C et al. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: Detection in remission marrow predicts outcome. Br J Haematol 1999; 105: 241-255 (Pubitemid 29197167)
42. Lucio P, Parreira A, van den Beemd MW, van Lochem EG, van Wering ER, Baars E et al. Flow cytometric analysis of normal B cell differentiation: A frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia 1999; 13: 419-427 (Pubitemid 29108081)
43. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109: 926-935 (Pubitemid 46220635)
44. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741
45. Neale GA, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004; 18: 934-938 (Pubitemid 38714617)
46. Malec M, van der Velden VH, Bjorklund E, Wijkhuijs JM, Soderhall S, Mazur J et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: Comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia 2004; 18: 1630-1636 (Pubitemid 39386341)
47. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598
48. Liu-Dumlao T, Kantarjian H, Thomas DA, O'Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: Current treatment options. Curr Oncol Rep 2012; 14: 387-394
49. He H, Shen Y, Zhu Y, Chen S. Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era. Front Med 2012; 6: 204-211